Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00985049 · ClinicalTrials.gov registry record

TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)

A clinical trial of Cardiovascular Diseases, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
350
Enrollment target
1
Study location

NCT00985049: Recruiting study of Cardiovascular Diseases, sponsored by Brigham and Women's Hospital.

NCT00985049 is a study of Cardiovascular Diseases that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 350 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00985049, a study of Cardiovascular Diseases, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
350 participants
Enrollment target
1
Study location

Study Summary

Hypothesis: The investigators hypothesize that genetic variants will alter gene expression in response to ischemia during cardiopulmonary bypass. To test this, the investigators will be taking small pieces of heart tissue from patients undergoing heart surgery before and after this period of ischemia. This will be compared to blood gene expression in blood cells and analyzed with the patients' genetic profile. This might allow us to assess the amount of inflammation that occurs when patients are on the heart-lung machine as well as examine the effects genes have on this critical time period.

Conditions Studied

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2009-03
Est. Completion 2025-12
Brigham and Women's Hospital

937 total trials

What NCT00985049 shows while recruiting

NCT00985049 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT00985049 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00985049 about?

NCT00985049 is a clinical study titled "TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)". Hypothesis: The investigators hypothesize that genetic variants will alter gene expression in response to ischemia during cardiopulmonary bypass. To test this, the investigators will be taking small pieces of heart tissue from patients undergoing heart surgery before and after this period of ischemi...

What is the current status of trial NCT00985049?

This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2009-03. Estimated completion is 2025-12.

What conditions does trial NCT00985049 study?

This clinical trial studies the following conditions: Cardiovascular Diseases.

Who is sponsoring clinical trial NCT00985049?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00985049 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00985049's enrollment target sits among peer trials

350 112th of 300 higher than 188 of 300 other Cardiovascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900575 · 350 participants · NA

    Cervical Cancer Detection Using Optical Spectroscopy

  • NCT01627821 · 350 participants · NA

    Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study

  • NCT02357654 · 350 participants · Phase 4

    GnRH for Luteal Support in IVF/ICSI/FET Cycles

  • NCT03997370 · 350 participants · Phase 1

    Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00985049, the US trial registry maintained by the National Library of Medicine. NCT00985049 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.